Kidney disease can cause significant hair loss. Waste buildup and nutrient imbalances weaken hair follicles. Patients may experience thinni...

The government is awarding Rs 10 crore to develop a sickle cell disease drug. This initiative addresses the disproportionate impact on trib...

Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-inco...

Drugs for four of these diseases -Tyrosinemia Type 1, Gaucher's Disease, Wilson's Disease and Dravet-Lennox Gastaut Syndrome - along with s...

Zydus Lifesciences on Monday said it has received an approval from the Drug Controller General of India (DCGI) for Oxemia (Desidustat), a f...

Consolidated total revenue from operations stood at Rs 3,655 crore during the quarter under review as compared to Rs 3,633 crore in the yea...

The pill technically called hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor can be given to both patients who are on dialysi...

PPH, if left untreated, can result in complications like anaemia in the postpartum period or aggravate mental health problems including pos...

As per the terms of the agreement, Sun Pharma will be the exclusive development and commercialisation partner for Triferic during the term ...

The committee noted that the prices of patented anti-cancer and antifungal drugs are "on the higher side" and cited the example of Rs 1 lak...

Anaemia commonly arises in kidney disease patients, because the kidneys no longer produce sufficient amounts of erythropoietin, a hormone w...

Vitamin B12 deficiency causes anaemia and subacute combined degeneration of the spinal cord, which leads to destruction and can present as ...

Hyderabad based Hetero pharma has launched biosimilar drug Rituximab under the brand name of MABALL, used in the treatment of blood cancer.

The team has created a class of molecules called immunotoxins to specifically target cancer cells, while leaving healthy cells unaffected.

Actorise is a biosimilar of 'Darbepoetin alfa', which is marketed by US-based Amgen under the brand Aranesp.

The company is all set to launch fifth biosimilar drug and seeks approvals for clinical trials and stem-cell treatment.

Swiss drugmaker Roche has filed its Avastin drug for use in previously untreated advanced breast cancer in Europe, the company said on Mond...